CIK 0000200406 · Large accelerated filer
JOHNSON & JOHNSON
Sign in to watch- Ticker
- JNJ
- Exchange
- NYSE
- Industry
- Pharmaceutical Preparations
- FY end
- Jan 3
- Incorporated
- NJ
- Entity type
- operating
- EIN
- 221024240
- Phone
- 732-524-2455
- Business address
- ONE JOHNSON & JOHNSON PLZ, NEW BRUNSWICK, NJ, 08933
- Former names
- JOHNSON & JOHNSON ET AL
- Open-market buys, last 90 days
- $0
- in 0 filings
- Open-market sales, last 90 days
- $16,898,386
- in 3 filings
Net −$16,898,386. Shares bought or sold at a price by officers, directors and 10% owners (Form 4 codes P and S). Grants, option exercises and tax withholding aren't counted.
Who's trading
90 days
Reading 100 more Form 4s from the SEC; this list fills in as they're read.
| Date | Insider | Transaction | Shares | Price | Value | Owned after |
|---|---|---|---|---|---|---|
| 2026-01-26 | Duato Joaquin CEO and Chairman of the Board | Sale | −51,218 | $220.99 | $11.3M | 79,634 |
| 2026-01-26 | Duato Joaquin CEO and Chairman of the Board | Sale | −48,782 | $221.48 | $10.8M | 30,852 |
| 2025-12-09 | Woods Eugene A. Director | Grant or award · Deferred Share Units | +185.53 | $202.12 | $37K | 5,058.07 |
| 2025-12-09 | HEWSON MARILLYN A Director | Grant or award · Deferred Share Units | +247.38 | $202.12 | $50K | 14,153.12 |
| 2025-12-09 | Pinto Daniel E Director | Grant or award · Deferred Share Units | +154.61 | $202.12 | $31K | 331.23 |
| 2025-11-26 | MORIKIS JOHN G Director | Purchase | +1,250 | $206.15 | $258K | 1,848.51 |
| 2025-10-17 | REED JOHN C EVP, Innovative Medicine, R&D | Option exercise | +21,721 | $157.92 | $3.4M | 32,379 |
| 2025-10-17 | REED JOHN C EVP, Innovative Medicine, R&D | Sale | −21,721 | $192.71 | $4.2M | 10,658 |
| 2025-10-17 | REED JOHN C EVP, Innovative Medicine, R&D | Option exercise · Employee Stock Options (Right to Buy) | −21,721 | $157.92 | $3.4M | 43,442 |
| 2025-09-09 | HEWSON MARILLYN A Director | Grant or award · Deferred Share Units | +280.79 | $178.07 | $50K | 13,816.87 |
| 2025-09-09 | Pinto Daniel E Director | Grant or award · Deferred Share Units | +175.49 | $178.07 | $31K | 175.49 |
| 2025-09-09 | Woods Eugene A. Director | Grant or award · Deferred Share Units | +210.59 | $178.07 | $37K | 4,841.4 |
| 2025-09-04 | Taubert Jennifer L EVP, WWC. Innovative Medicine | Option exercise | +56,471 | $101.87 | $5.8M | 234,484 |
| 2025-09-04 | Taubert Jennifer L EVP, WWC. Innovative Medicine | Sale | −56,471 | $177.81 | $10.0M | 178,013 |
| 2025-09-04 | Taubert Jennifer L EVP, WWC. Innovative Medicine | Option exercise · Employee Stock Options (Right to Buy) | −56,471 | $101.87 | $5.8M | 0 |
| 2025-08-29 | Forminard Elizabeth Executive VP, General Counsel | Option exercise | +11,521 | $115.67 | $1.3M | 22,423 |
| 2025-08-29 | Forminard Elizabeth Executive VP, General Counsel | Shares withheld for taxes | −9,570 | $177.20 | $1.7M | 12,853 |
| 2025-08-29 | Forminard Elizabeth Executive VP, General Counsel | Option exercise · Employee Stock Options (Right to Buy) | −11,521 | $115.67 | $1.3M | 0 |
| 2025-08-22 | Duato Joaquin CEO and Chairman of the Board | Option exercise | +125,824 | $101.87 | $12.8M | 401,791 |
| 2025-08-22 | Duato Joaquin CEO and Chairman of the Board | Sale | −125,824 | $179.21 | $22.5M | 275,967 |
Page 14 of 19 · 365 trades